
Accenture PLC (ACN), a large-cap growth stock in the Computer Services sector, received a 77% rating from Validea's Patient Investor model, which is based on Warren Buffett's strategy focusing on predictable profitability, low debt, and reasonable valuations. ACN demonstrated strength by passing criteria for earnings predictability, debt service, return on equity, free cash flow, and expected return. However, its 77% score falls just below the 80% threshold typically indicating 'some interest' for the strategy, with the stock failing on the initial rate of return test.
Accenture PLC (ACN) demonstrates strong fundamental alignment with the Warren Buffett-inspired 'Patient Investor' model, scoring 77% according to a Validea fundamental report. This score, while strongly positive, falls just short of the 80% threshold that the model typically uses to indicate significant interest. The company's strengths are evident as it passed criteria for earnings predictability, debt service, return on equity, return on total capital, and free cash flow, pointing to a high-quality enterprise with predictable profitability and a healthy balance sheet. However, the analysis reveals a key weakness: the stock failed the 'Initial Rate of Return' test. This specific failure suggests that, despite its strong operational and financial metrics, ACN's current market valuation may not offer a sufficient margin of safety or an attractive enough entry point to meet the strategy's stringent value criteria. The 'Neutral' rating on share repurchases further indicates that capital return via buybacks is not a significant positive driver for the score.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment